Valuation: ReShape Lifesciences

Market Cap 15.72M 13.79M 12.77M 11.75M 22.23M 1.5B 22.66M 152M 59.7M 739M 59.04M 57.75M 2.55B P/E 2026 *
-3.18x
P/E 2027 * -2.45x
Enterprise Value 15.72M 13.79M 12.77M 11.75M 22.23M 1.5B 22.66M 152M 59.7M 739M 59.04M 57.75M 2.55B EV / Sales 2026 *
105x
EV / Sales 2027 * 62.9x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 132K 122K 112K 212K 14.36M 216K 1.45M 570K 7.05M 563K 551K 24.35M 250K 219K 203K 187K 353K 23.93M 360K 2.42M 949K 11.75M 939K 918K 40.58M
Net income -4.89M -4.29M -3.97M -3.66M -6.91M -468M -7.05M -47.35M -18.57M -230M -18.36M -17.96M -794M -7.77M -6.81M -6.31M -5.81M -10.98M -744M -11.2M -75.22M -29.5M -365M -29.17M -28.54M -1.26B
Net Debt - -
Logo ReShape Lifesciences
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-